Symbiotec eyes IPO to give exit to PE investors; can it command a high valuation?
Stay Home. Read Quality News
Advertisement
  • Home
  • Healthcare
  • Symbiotec eyes IPO to give exit to PE investors; can it command a high valuation?

Symbiotec eyes IPO to give exit to PE investors; can it command a high valuation?

By Debjyoti Roy

  • 17 Oct 2024
Premium
Symbiotec eyes IPO to give exit to PE investors; can it command a high valuation?

Bulk drug maker Symbiotec Pharmalab is planning to explore the possibility of floating an initial public offering in the.........

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Become a Premium member
Already a member? Click here to log in.